3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Endocrine
1
CNS
1
Breast
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
Magnetic Resonance Spectroscopy
15
lutetium Lu 177 dotatate
14
Specimen Handling
14
cabozantinib
10
Nivolumab
10
pembrolizumab
8
Everolimus
8
gallium Ga 68 dotatate
7
Ipilimumab
6
Cisplatin
6
Carboplatin
6
Etoposide
5
trametinib
4
olaparib
4
lenvatinib
4
X-Rays
4
Lutetium-177
4
Cyclophosphamide
4
CTLA-4 Antigen
4
fluorodopa F 18
3
fludarabine
3
dabrafenib
3
cemiplimab
3
Temozolomide
3
Surveys and Questionnaires
3
Phantoms, Imaging
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
belzutifan
×
Endocrine
×
90 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA